The global hepatic encephalopathy treatment market is set to achieve significant growth, with projections indicating an increase from USD 1583 Million in 2023 to USD 2971.51 Million by 2033, reflecting a CAGR of 6.5% during the forecast period. The market witnessed a moderate growth rate of 3.9% CAGR during the historical period of 2018 to 2022, which is now accelerating due to a surge in liver-related disorders worldwide.
Key Market Drivers:
The rise in liver diseases, including cirrhosis and non-alcoholic fatty liver disease (NAFLD), is a primary factor fueling market growth. As hepatic encephalopathy stems from the liver’s inability to eliminate toxins from the bloodstream effectively, leading to toxin buildup in the brain, the demand for comprehensive treatment solutions continues to grow.
Understanding Hepatic Encephalopathy:
Hepatic encephalopathy is a severe condition that can range from mild to life-threatening, characterized by symptoms such as:
- Cognitive dysfunction: Confusion and personality changes.
- Neurological issues: Tremors and loss of motor control.
- Severe outcomes: Potential progression to coma in advanced stages.
Effective management of HE involves addressing its root causes, primarily liver diseases like cirrhosis. Treatments include:
- Medication: To reduce toxin levels in the bloodstream.
- Dietary modifications: Tailored to support liver health.
- Lifestyle changes: Including alcohol cessation and regular medical monitoring.
Future Outlook:
With advancements in medical research and increased awareness, the HE treatment market is poised for steady growth. Pharmaceutical innovations and comprehensive management strategies targeting liver health will play a critical role in shaping the market landscape.
As the prevalence of liver disorders continues to rise, so does the importance of effective hepatic encephalopathy treatments. The robust growth projected for the global HE treatment market underscores the urgency and potential for innovation in managing this critical condition, paving the way for improved patient outcomes and a healthier global population.
Accelerated Market Demand: Find Comprehensive Insights and Trends in Our Full Report!
Key Takeaways from the Market Study:
- The Hepatic encephalopathy treatment market is expected to grow at a value of 6.5% CAGR in the forecast period 2023-2033
- Hospital pharmacies are expected to hold 49% of the market share in 2023 for Hepatic encephalopathy treatment market.
- North America is expected to possess 44% market share for Hepatic encephalopathy treatment market in 2023.
- Asia Pacific Hepatic encephalopathy treatment market size is expected to possess 39% market share in 2023.
“The Hepatic Encephalopathy Treatment Market is also being driven by the increasing adoption of combination therapies for HE.” states an FMI analyst
Competitive Landscape:
Key players in the hepatic encephalopathy treatment market are Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc.
- Mallinckrodt Pharmaceuticals has developed and marketed several medications for the treatment of Hepatic Encephalopathy that include Ofirmev and Terlipressin (Glypressin) injection. In addition to these medications, Mallinckrodt Pharmaceuticals has also sponsored clinical research into the treatment of HE, with a focus on developing new treatments and improving the understanding of the condition.
- Salix Pharmaceuticals has developed Xifaxan (rifaximin) tablets. Xifaxan is an antibiotic medication that works by reducing the levels of bacteria in the gut, which can help reduce the production of toxins that contribute to the development of HE.
Key Segments Profiled in the Hepatic Encephalopathy Treatment Industry Survey
Drug Class:
- Antibiotics
- Laxatives
- L-ornithine
- L-aspartate
Diagnosis:
- Blood Tests
- CT Scan
- Liver Functioning Tests
Route of Administration:
- Oral
- Injectable
- Intravenous
- Others
Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube